Works Cited

 

1.                  www.niaid.nih.gov/daids

2.                  Kane, B.  2000.  HIV vaccines: inch by inch.  Annals of Internal Medicine.  133:489-490.

3.                  Dimitrov, D.S. and C.C. Broder.  1997.  HIV and membrane receptors.  For www.AccessScience.com

4.                  Prescott, L.M. et al.  1999.  Microbiology 4th Ed.  McGraw-Hill.  Boston.

5.                  Esparza, J. et al.  2000.  Accelerating the development and future availability of HIV-1 vaccines: why, when, where, and how?  Lancet.  355:2061-2066.

6.                  Thompson, R.C.A.  2000.  Molecular epidemiology of infectious diseases.  Oxford UP.  New York.

7.                  Stryer, L.  1995.  Biochemistry 4th Ed.  W.H. Freeman and Co.  New York.

8.                  Greene, W.C.  1991.  Mechanisms of disease:  The molecular biology of Human Immunodeficiency Virus Type 1 infection.  New England Journal of Medicine. 324:308.

9.                  Bouhdoud, L.P. et al.  2000.  T-cell receptor mediated anergy of a human immunodeficiency virus (HIV) gp120 specific CD4 cytotoxic T-cell clone, induced by a natural HIV type 1 variant peptide.  Journal of Virology.  74:2121-2128.

10.              Rubenstein, A. et al.  1999.  Immunologic responses of HIV-1 infected study subjects to immunization with a mixture of peptide protein derivative-V3 loop peptide conjugates.  Journal of AIDS.  22:467-476.

11.              Bartlett, J.G.  2001.  The guide to living with HIV infection 5th ed.  Johns Hopkins UP.  Baltimore and London.

12.              Mitsuya, H. et al.  1987.  Strategies for antiviral therapy in AIDS.  Nature.  325: 773-778.

13.              Ward, D.E. ed.  1999.  AmFar AIDS handbook:  The complete guide to understanding HIV and AIDS.  W.W. Norton and Co.  London.

14.              HIV Newsline.  1996 June.  How protease inhibitors work.

15.              Markowitz, M.  1997.  Protease inhibitors: what they are, how they work, when to use them.  IAPAC.  Chicago.

16.              Bartlett, J.G. ed.  2000.  The Johns Hopkins Hospital 2000-2001 guide to medical care of patients with HIV infection.  8th Ed.  Lipincott, Williams, and Wilkins.  Philadelphia.

17.              Keiser, P.  2002.  Role of Sequencing in Therapy Selection.  Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology.  29: S19-S27.

18.              Casado, J.L., et al.  1998.  Predictors of long term response to protease inhibitor therapy in a cohort of HIV infected patients.  AIDS.  12: F135-F139.

19.              Michelet C. et al.  Ritonavir-saquinavir dual protease inhibitor compared to ritonavir alone in HIV infected patients.  Antimicrobial Agents and Chemotherapy.  45: 12: 3393-3402.

20.              Phillips, A.N. et al.  2001.  Durability of HIV-1 viral suppression over 3.3 years with multi-drug antiretroviral therapy in previously drug naïve individuals.  AIDS.  15: 2379-2384.

21.              Lorenzi, P. et al.  1997.  Toxicity, efficacy, plasma drug concentrations and protease mutations in patients with advanced HIV infection treated with ritonavir plus saquinavir.  AIDS.  11: F95-F-99.

22.              Casado, J.L. et al.  2002.  Plasma drug levels, genotypic resistance, and virological response to a nelfinavir plus saquinavir containing regimen.  AIDS.  16: 47-52.

23.              Kodama, E.I. et al.  2001.  4’-Ethynyl nucleoside analogs: potent inhibitors of multidrug-resistant HIV variants in vitro.  Antimicrobial Agents and Chemotherapy.  45: 5: 1539-1546.

24.              Murray, P.R. et al.  1998.  Medical Microbiology 3rd Ed.  Mosby.  St. Louis.

25.              Campiani, C. et al.  1999.  Pyrrolobenzoxazepinone derivatives as non-nucleoside HIV-1 RT inhibitors: further structure-activity relationship studies and identification of more potent broad spectrum HIV-1 RT inhibitors with antiviral activity.  Journal of Medical Chemistry.  42: 4462-4470.

26.              Tomlinson, J.A. et al.  1974.  The inhibition of infection of cucumber mosaic virus and influenza virus by extracts from Phytolacca americana.  Journal of General Virology.  22:225-232. 

27.              Teltow, G.J. et al.  1983.  Inhibition of herpes simplex virus DNA synthesis by pokeweed antiviral protein.  Antimicrobial Agents and Chemotherapy.  23: 390.

28.              Kurinov, I.V. et al.  1999.  X-ray crystallographic analysis of the structural basis for the interactions of pokeweed antiviral protein with its active site inhibitor and ribosomal RNA substrate analogs.  Protein Science.  8: 1765-1772.

29.              Uckun, F. et al.  1999.  Toxicity, biological activity, and pharmacokinetics of TXU-pokeweed antiviral protein in chimpanzees and adult patients infected with HIV.  Pharmacology and Experimental Therapeutics.  291: 1301-1307.

30.              Uckun, F. et al.  1998.  TXU-pokeweed antiviral protein as a potent inhibitor of HIV.  Antimicrobial Agents and Chemotherapy.  42: 383-388.

31.              Schuster, D.I.  2000.  Fullerene.  For www.AccessScience.com

32.              Borkow, G. et al.  1999.  The thiocarboxanilide nonnucleoside inhibitor UC781 restores antiviral activity of AZT against AZT-resistant HIV-1.  Antimicrobial Agents and Chemotherapy.  43: 259-263.

33.              Acosta, E.P.  2002.  Pharmacokinetic enhancement of protease inhibitors.  Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology.  29: S11-S18.

34.              Davey, R.T. Jr. et al.  2000.  Immunologic and virologic effects of subcutaneous interleukin 2 in combination with antiretroviral therapy.  A randomized controlled trial.  Journal of the American Medical Association.  284:183-189.

35.              Sandström, E. Nordic VAC-04 Study Group.  1999.  Therapeutic immunisation with recombinant gp160 in HIV-1 infection: a randomised double-blind placebo-controlled trial.  Lancet.  353:173542.

36.              Shen, X. and R.F. Siciliano.  2000.  Preventing AIDS but not HIV-1 infection with a DNA vaccine.  Science.  290:463-465.

37.              Sabbaj, S. NIAID AIDS Vaccine Evaluation Group.  2000.  Cytokine profiles in seronegative volunteers immunized with a recombinant canarypox and gp120 prime-boost HIV-1 vaccine.  AIDS.  14:1365-1373.

38.              Verrier, F., S. et al.  2000.  A human immunodeficiency virus prime-boost immunization regimen in humans induces antibodies that show interclade cross reactivity and neutralize several X4-, R5-, and dualtropic clade B and C primary isolates.  Journal of Virology.  74:10025-10033.

39.              Moss, R.B. et al.  2000.  T-helper cell proliferative responses to whole-killed human immunodeficiency virus type 1 (HIV-1) and p24 antigens of different clades in HIV-1 infected subjects vaccinated with HIV-1 immunogen (Remune).  Clinical and Diagnostic Laboratory Immunology.  7:724-726.

40.              Murphy, C.G. et al.  2000.  Vaccine protection against simian immunodeficiency virus by recombinant strains of herpes simplex virus.  Journal of Virology. 74:7745-7753.

41.              Auerbach, J.D. et al. eds.  1994.  AIDS and behavior.  An integrated approach.  National Academy Press.  Washington D.C.

42.              Powderly, W.G.  2002.  Long-term exposure to lifelong therapies.  Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology.  29: S28-S40

43.              Bartlett, J.A.  2002.  Addressing the challenges of adherence.  Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology.  29: S2-S10.

44.              Baldwin, J.D. and J.I. Baldwin.  1998.  Behavior principles in everyday life.  3rd Ed.  Prentice Hall.  New Jersey.

45.              Wenger, N. and A. Gifford.  1999.  Patient characteristics and attitudes associated with antiretroviral adherence.  6th Conference on Retroviruses and Opportunistic Infections.  Chicago.

46.              Bruhn, J.G.  1999.  Social and psychological aspects of care.  Ch.15 in Muma, R.D. et al. eds.  HIV manual for healthcare professionals.  2nd Ed.  Appleton and Lange.  Stamford.

47.              Ortega, M.A.  1999.  Social worker assessment and intervention.  Ch.13 in Muma, R.D. et al. eds.  HIV manual for healthcare professionals.  2nd Ed.  Appleton and Lange.  Stamford.

48.              Comer, R.J.  1998.  Abnormal Psychology 3rd Ed.  W.H. Freeman and Co.  New York.

49.              Markowitz, J.D. et al.  1994.  Treating depression in HIV-positive patients.  AIDS.  8: 403-412.

50.              American Psychiatric Association.  1994.  Diagnostic and Statistical Manual of Mental Disorders.  4th Ed.  American Psychiatric Press.  Washington D.C.

51.              Avery, E.N.  1999.  Psychiatric care.  Ch.14 in Muma, R.D. et al. eds.  HIV manual for healthcare professionals.  2nd Ed.  Appleton and Lange.  Stamford.

52.              Navia, B.A. et al.  1986.  The AIDS dementia complex, 1. Clinical features.  Annals of Neurology.  19: 517-524.

53.              Sewell, D.D. et al.  1994.  HIV associated psychosis:  A longitudinal study of 20 cases.  American Journal of Psychiatry.  151: 237-242.

54.              Tomb, D.  1995.  Psychiatry 5th Ed.  Williams and Wilkins.  Baltimore.

55.              Thomas, M.  1999.  An exploration of change: The influence of combination therapies on PWA support groups.  Ch.3 in Shernoff, M. ed. AIDS and mental healthcare practice.  Clinical and policy issues.  The Haworth Press.  New York.

56.              www.gmhc.org

57.              Gushue, G.V.  1997.  Beyond science: Miracles, miracle cures, and AIDS-the role of the therapist.  In Wicks, L.A. ed. Psychotherapy and AIDS: The human dimension.  Taylor and Francis.  Washington D.C.

58.              Mellors, M.P. et al.  2001.  Transcending the suffering of AIDS.  Journal of Community Health Nursing.  18: 235-246.

59.              Coward, D.D.  1996.  Self transcendence: A resource for healing at the end of life.  Issues in Mental Health Care Nursing.  17: 275-288.

60.              Kübler-Ross, E.  1969.  On death and dying.  Macmillan.  New York.

61.              Shernoff, M.  1999.  Dying well: Counseling end-stage clients with AIDS.  Ch.15 in Shernoff, M. ed.  AIDS and mental healthcare practice.  Clinical and policy issues.  The Haworth Press.  New York.

62.              Rabkin, J.  et al.  1994.  Good doctors, good patients: Partners in HIV treatment.  NCN Publishers.  New York.